Genetic Immunity

Executive Summary

Genetic Immunity is a Hungarian biotechnology company founded in 2006, based in Budapest, specializing in therapeutic plasmid DNA-based immunotherapies for cancers and viral infections. The company's platform aims to harness the body's immune system to target diseases, with a vision to improve global health outcomes. Despite its long-standing presence, the company remains private with limited public disclosures on funding, clinical pipeline, or partnerships. As of 2026, there are no reported commercial products or publicly available trial data, suggesting an early-stage development phase. The biotech sector in Hungary is growing, but Genetic Immunity's specific progress is unclear, warranting cautious optimism.

Upcoming Catalysts (preview)

• TBDClinical Trial Updates30% success
• TBDStrategic Partnership or Licensing Deal25% success
• TBDRegulatory Milestone (e.g., IND approval)20% success